# Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

> **NCT05610202** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 137 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** TQB3702 tablets

## Key facts

- **NCT ID:** NCT05610202
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 137 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610202, "Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05610202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*